{"name":"Zai Lab","slug":"zai-lab","ticker":"ZLAB","exchange":"NASDAQ","domain":"zailaboratory.com","description":"Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceutical","hq":"Shanghai, China / Cambridge, MA","founded":0,"employees":"1784","ceo":"Samantha Du","sector":"Oncology / China Bridge","stockPrice":20,"stockChange":-0.47,"stockChangePercent":-2.3,"marketCap":"$2.2B","metrics":{"revenue":460156000,"revenueGrowth":17,"grossMargin":10.5,"rdSpend":0,"netIncome":-175536992,"cash":689572992,"dividendYield":0,"peRatio":-11.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ZEPZELCA patent cliff ($1.2B at risk)","drug":"ZEPZELCA","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"ZEJULA patent cliff ($1.5B at risk)","drug":"ZEJULA","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Brivanib 400 mg, BID","genericName":"Brivanib 400 mg, BID","slug":"brivanib-400-mg-bid","indication":"Hepatocellular carcinoma (Phase 2)","status":"phase_2"},{"name":"Brivanib 800 mg, QD","genericName":"Brivanib 800 mg, QD","slug":"brivanib-800-mg-qd","indication":"Hepatocellular carcinoma","status":"phase_2"},{"name":"ZL-1109 (VRDN-003)","genericName":"ZL-1109 (VRDN-003)","slug":"zl-1109-vrdn-003","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"ZL-1310","genericName":"ZL-1310","slug":"zl-1310","indication":"FGFR-positive or FGFR-altered solid tumors","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Investigator's Choice of Therapy","genericName":"Investigator's Choice of Therapy","slug":"investigator-s-choice-of-therapy","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Brivanib 400 mg, BID","genericName":"Brivanib 400 mg, BID","slug":"brivanib-400-mg-bid","phase":"phase_2","mechanism":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","indications":["Hepatocellular carcinoma (Phase 2)","Advanced solid tumors (Phase 2)"],"catalyst":""},{"name":"Brivanib 800 mg, QD","genericName":"Brivanib 800 mg, QD","slug":"brivanib-800-mg-qd","phase":"phase_2","mechanism":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","indications":["Hepatocellular carcinoma","Advanced solid tumors"],"catalyst":""},{"name":"Investigator's Choice of Therapy","genericName":"Investigator's Choice of Therapy","slug":"investigator-s-choice-of-therapy","phase":"phase_3","mechanism":"Investigator's Choice of Therapy is a flexible treatment approach where the treating physician selects from approved or standard-of-care therapeutic options based on individual patient characteristics.","indications":[],"catalyst":""},{"name":"ZL-1109 (VRDN-003)","genericName":"ZL-1109 (VRDN-003)","slug":"zl-1109-vrdn-003","phase":"phase_3","mechanism":"ZL-1109 (VRDN-003) is a small molecule targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ZL-1310","genericName":"ZL-1310","slug":"zl-1310","phase":"phase_3","mechanism":"ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-positive or FGFR-altered solid tumors","Cholangiocarcinoma with FGFR alterations"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Zai Lab Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Zai Lab reported fourth quarter and full year 2023 financial results, with revenue of $143.4 million and a net loss of $143.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Zai Lab Announces Collaboration with BeiGene to Develop and Commercialize Cancer Therapies in China","summary":"Zai Lab and BeiGene announced a collaboration to develop and commercialize cancer therapies in China, expanding Zai Lab's presence in the country.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Zai Lab Receives Approval for ZEPZELCA in China","summary":"Zai Lab received approval from the National Medical Products Administration (NMPA) for ZEPZELCA, a cancer therapy, in China.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPMldGQzU4VTJyejMxajdMNE5YcXlzYmFDd1RCdUhjOWhpaXl4WklWNmpXNXVGa000eHpXeGZneUhWa0FmelJBWXJqVE04UUUyblNzam5vX2VzWW1kMElGd0RuWkk4OUNzaG1Kb05jbEVvNzI2cG1USFRhMzlaWHNvUjBsU0dETmZjVUFqNV8xRjdDTXZ6TGc?oc=5","date":"2026-04-06","type":"pipeline","source":"Seeking Alpha","summary":"Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative (NASDAQ:ZLAB) - Seeking Alpha","headline":"Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative (NASDAQ:ZLAB)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"deal","source":"simplywall.st","summary":"A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News - simplywall.st","headline":"A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPRV9sYWFLSkV3VkRaR2p1VWtRMmtOMUhnYUttV2F4Ym1lQjJHV2pBeERSYWEzNUNKRFh0dlZsRHUxZ1RmdFFlUEtyOTA2bDhpVHFtckQ1QnYxZHN4QVQ1US1jTFR6VnhVenktZnFnSjlrLWxGbFFtNllCajlfd3ZaTU52OHFZQ19LU3ZyQzlKV2ItSnJZeGdCOUp6dEFRbHlDQUhFeFVGUldHQ0RWUjZKMGlxYmdIeWlqeWYwTW12QnpWSlc4M3lRTmc1WlZGWUtqamo0Y1d5OHc2ZDhLcW82RDI3VDFNTE5GbkUw?oc=5","date":"2026-02-26","type":"earnings","source":"Business Wire","summary":"Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - Business Wire","headline":"Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-14","type":"pipeline","source":"simplywall.st","summary":"Is Zai Lab (ZLAB) Resetting After Multi‑Year Share Price Declines? - simplywall.st","headline":"Is Zai Lab (ZLAB) Resetting After Multi‑Year Share Price Declines?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOWk9ub2t0bEhwUjFEOFUyNTBTRG9GajhOUU1oWFJUSFRpUTlVMDVNY19GOUZUNHZQRGVBUFhNaXp0V1BUN1hiZ2NsNXNMeUV6ejFkSThhYTNrUkU2bGFlTkg1QXNWN0pQejdfbHpfaUlzNDF0MXlFWUM4VnM2QTRyMUx2TkNBOXY1cy1RMkVLUGZMbHVBTDlReHgwM1p6c0RGTWlyUDBQYzI4cElGTEF5VWpwcVdGRnpoVy1adWd3?oc=5","date":"2026-01-05","type":"pipeline","source":"AD HOC NEWS","summary":"Zai Lab Ltd (ZLAB): The High-Risk Biotech Bet Everyone’s Suddenly Watching - AD HOC NEWS","headline":"Zai Lab Ltd (ZLAB): The High-Risk Biotech Bet Everyone’s Suddenly Watching","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQUkRHRVN2ejlfTGcwSUFvWXNWSGpmQ2NSRU1PeFF0YTJMczIydm1QM0YzY1lRcVF3SXBGeU9ZaW9XNmJ2RjI5UFVRSWdUTE1fbUZCR2VuMGVDWE4yRWcyMXBoZGJ5RUdjcDZoYV9lSWFwVWwyc1UzVFRrWjV2Sm5WZWFBZ2RTdjhHaFEzV1lmT2FPQjB0bHNiMkowMXlrTWo2ZDU4T0RFUVRpV2VNbGNnMTBLUENBdnlHR1FuTERWZFdlNi1UWkIxRjRTVUs0UFpDSW9MUGFBNHdBeTZaVWhzUG5wQU1YQQ?oc=5","date":"2025-12-24","type":"regulatory","source":"TechStock²","summary":"Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025 - TechStock²","headline":"Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNVjZ5cXdXQTFKUzBjRkdSWHBzdGw5d0ZoNS1zdXc1dlJ4QWZHdWY3MTBJN3lPTWFVZlQyT01FSVRiSDItMFpld3lTeXZiaWE1RjJ5SEdTWnZZempQX0xZYnNKUmhaZml2Y3hDYXljSzd3TDFpMG1JZkxMM0JfX0lnd0JyOFFuQnNnY2ZnZ25lUnJ2Q25TczBpM05GRlp2WFEtNzhVMzNQaHpIVFJSamh2X1NFT2N2bWVQVVo5bEx5VGVUVTVlUDhyREVxY0xITGl1Q1VBWGx0YklGWUJ1Qnl6dG5XNUVaQQ?oc=5","date":"2025-12-23","type":"regulatory","source":"Benzinga","summary":"FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga","headline":"FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-06","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive - simplywall.st","headline":"Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYnljNUVGMDh3WTl2VHBLQ0ZZRC13YUVLNzRZTER1eXJGdTVuWWlRV21vdTVZQVFwXzZQNmp2S3VsNll6TGNKbUxjMkZTMTJkYmN6MEVNNms2eHItQ3dadHBOVXBUZEZkaFBkWTlhdkNvUWdldWtxakMzOHFIV3VXb3Y4OXIyOEIwSVJaSWhPVlZFak4zY2lzNWphZ0x6QzRnbVZ5RXJZV0pyWEhNLU9mcFVWTDc3ekxKbzgyOTdZYUxUN1hFNUc3YlhuVTR4UkF3cVFfQTVROVY4Zw?oc=5","date":"2025-10-31","type":"pipeline","source":"Business Wire","summary":"Zai Lab Announces Participation in Investor Conferences in November and December 2025 - Business Wire","headline":"Zai Lab Announces Participation in Investor Conferences in November and December 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPUzNEcEpSb2Q0RkVlaGZ1ZXQ5a2dnRHBSU3VZQldnNE1kS2Y0ZjVQVHdiXzhmaEFtUWRrRGFvZTdMTjB6cEhOMmtlcm9seWZpbHBfa2l2T2Y4WXU4RHZnVmtlc29XN1E4bldFSDRzR1hqSkdLTmRIeE9sQmxjMXpuSU9sb3pRSy1LVFRTYVFkMFNDZw?oc=5","date":"2025-09-11","type":"pipeline","source":"thebambooworks.com","summary":"Zai Lab under pressure over clinical results and rival drugs - thebambooworks.com","headline":"Zai Lab under pressure over clinical results and rival drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxORDhqOTlvWWJwV2drUUpJLUd4LUxDc0VKME1fWXZ6ZHFzYUx0eGtVV2d6SWZaSUY3WFhaZ0lXV2tYUGk1ZFcxVlo2azVFY2NkMTFSVkY0c3hXRkZFSXg3U2VqSmNuT05WbjNCZ3JQdlFLQXl0R1N4dWd4Z1NQb01FTUlINElhemR0TkNGUDVGdXBNX2dBWlVDRDBUTjM2aW9kYXRVb2ln?oc=5","date":"2025-09-10","type":"pipeline","source":"Investor's Business Daily","summary":"Rumored Trump Move Rattles China-Based Biotech Stocks - Investor's Business Daily","headline":"Rumored Trump Move Rattles China-Based Biotech Stocks - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxNZVpWVWhDVS1tMWQ3VVBpZy1DVERVbDZKOVdiX25idnhlaEN2aXJmUll4YzhNcVppa2piR1lJSEhhVWd0dGNEZUE2RGcxNERIdlFVU2NodHBkQmNYaC1JMEVlaWFGczl5alY4azJCYm1UdDQ2RjVOejV3eDBUMTE2dF9LcFlfSjRYaW5faXZzUVR6QmcwMU90WU83WExscHZOclJDQmdXM01WWEZhQTUxYS1mTjJuRkZHM1pyTTJnbnVhdnJMemI2VUZFX3V5Q2NvSjg0R0wyU24yck56YTNmZTl0UG5XMWlnbzNGME5YUmhVRWFBVHpOUUZQZEdpRkkyTnlzOUZ3MDVHOWFOOWZlcEhFemlINWFDdnE5M1MzR2tKRkZQa3lVUHdCTGtNNUlhdjViU2J3RF9mMG9G?oc=5","date":"2025-01-10","type":"pipeline","source":"Business Wire","summary":"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore - Business Wire","headline":"Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong S","sentiment":"neutral"}],"patents":[{"drugName":"ZEPZELCA","drugSlug":"nitroglycerin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"ZEJULA","drugSlug":"niraparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BeiGene","Innovent Biologics","Sino Biopharmaceutical"],"therapeuticFocus":["Oncology"],"financials":{"source":"yahoo_finance","revenue":460156000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":460156000},{"period":"2024-12-31","value":398988000},{"period":"2023-12-31","value":266719000},{"period":"2022-12-31","value":215040000}],"grossProfit":269075000,"grossProfitHistory":[{"period":"2025-12-31","value":269075000},{"period":"2024-12-31","value":251128000},{"period":"2023-12-31","value":170903000},{"period":"2022-12-31","value":141022000}],"rdSpend":220904000,"rdSpendHistory":[{"period":"2025-12-31","value":220904000},{"period":"2024-12-31","value":234504000},{"period":"2023-12-31","value":265868000},{"period":"2022-12-31","value":286408000}],"sgaSpend":277605000,"operatingIncome":-223572000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-223572000},{"period":"2024-12-31","value":-273947000},{"period":"2023-12-31","value":-374140000},{"period":"2022-12-31","value":-392886000}],"netIncome":-175537000,"netIncomeHistory":[{"period":"2025-12-31","value":-175537000},{"period":"2024-12-31","value":-257103000},{"period":"2023-12-31","value":-334620000},{"period":"2022-12-31","value":-443286000}],"eps":-1.6,"epsHistory":[{"period":"2025-12-31","value":-1.6},{"period":"2024-12-31","value":-2.6},{"period":"2023-12-31","value":-3.5},{"period":"2022-12-31","value":-4.6}],"cash":679573000,"cashHistory":[{"period":"2025-12-31","value":679573000},{"period":"2024-12-31","value":449667000},{"period":"2023-12-31","value":790151000},{"period":"2022-12-31","value":1008470000}],"totalAssets":1172384000,"totalLiabilities":456884000,"totalDebt":224259000,"equity":715500000,"operatingCashflow":-150789000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-150789000},{"period":"2024-12-31","value":-214869000},{"period":"2023-12-31","value":-198178000},{"period":"2022-12-31","value":-367642000}],"capex":-13424000,"capexHistory":[{"period":"2025-12-31","value":-13424000},{"period":"2024-12-31","value":-61522000},{"period":"2023-12-31","value":-8491000},{"period":"2022-12-31","value":-24984000}],"freeCashflow":-164213000,"dividendsPaid":null,"buybacks":null,"employees":1784,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":65070000,"ebit":-47939000,"ebitda":-43995000,"period":"2026-03-31","revenue":99611000,"epsBasic":-0.5,"netIncome":-51016000,"rdExpense":65591000,"epsDiluted":-0.5,"grossProfit":61276000,"operatingIncome":-69279000},{"sga":73039000,"ebit":-51975000,"ebitda":-48059000,"period":"2025-12-31","revenue":127597000,"epsBasic":-0.5,"netIncome":-50409000,"rdExpense":61633000,"epsDiluted":-0.5,"grossProfit":65266000,"operatingIncome":-68264000},{"sga":70106000,"ebit":-34563000,"ebitda":-30662000,"period":"2025-09-30","revenue":116095000,"epsBasic":-0.3,"netIncome":-35963000,"rdExpense":47928000,"epsDiluted":-0.3,"grossProfit":69212000,"operatingIncome":-47968000},{"sga":71038000,"ebit":-39465000,"ebitda":-35730000,"period":"2025-06-30","revenue":109977000,"epsBasic":-0.4,"netIncome":-40727000,"rdExpense":50614000,"epsDiluted":-0.4,"grossProfit":66757000,"operatingIncome":-51045000},{"sga":63422000,"ebit":-47251000,"ebitda":-43793000,"period":"2025-03-31","revenue":106487000,"epsBasic":-0.4,"netIncome":-48438000,"rdExpense":60729000,"epsDiluted":-0.4,"grossProfit":67840000,"operatingIncome":-56295000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":20,"previousClose":20.47,"fiftyTwoWeekHigh":44.34,"fiftyTwoWeekLow":15.96,"fiftyTwoWeekRange":"15.96 - 44.34","fiftyDayAverage":20.36,"twoHundredDayAverage":24,"beta":0.84,"enterpriseValue":21402828800,"forwardPE":-11.8,"priceToBook":3.09,"priceToSales":4.88,"enterpriseToRevenue":46.51,"enterpriseToEbitda":-99.81,"pegRatio":0,"ebitda":-214424000,"ebitdaMargin":-46.6,"freeCashflow":-92507872,"operatingCashflow":-150788992,"totalDebt":224259008,"debtToEquity":31.3,"currentRatio":2.45,"returnOnAssets":-12.2,"returnOnEquity":-22.6,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":34.39,"targetHighPrice":52,"targetLowPrice":21.6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.9,"institutionHeldPercent":33.5,"sharesOutstanding":112354858,"floatShares":959930116,"sharesShort":5497720,"shortRatio":6.87,"shortPercentOfFloat":4.9,"epsTrailing":-1.7,"epsForward":-1.7,"revenuePerShare":4.2,"bookValue":6.47,"officers":[{"age":59,"name":"Dr. Ying  Du Ph.D.","title":"Founder, Chairperson & CEO"},{"age":55,"name":"Mr. Joshua L.  Smiley","title":"President & COO"},{"age":61,"name":"Dr. Rafael G.  Amado M.D.","title":"President and Head of Global Research & Development"},{"age":57,"name":"Dr. Yajing  Chen Ph.D.","title":"Chief Financial Officer"},{"age":59,"name":"Mr. Frazor Titus  Edmondson III, J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":null,"name":"Ms. Christine  Chiou","title":"Senior VP & Head of Investor Relations"},{"age":61,"name":"Dr. James  Yan DABT, M.D., Ph.D.","title":"Chief Operating Officer of R&D"},{"age":47,"name":"Mr. Tong  Zhu","title":"Chief Commercial Officer of Greater China"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.zailaboratory.com","phone":"86 21 6163 2588"}}